Seshadri Neervannan - 15 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Operating Officer
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 15 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 16:35:26 UTC
Previous filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Neervannan Seshadri	Chief Operating Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE	/s/ Jeffrey Farrow, Attorney-in-Fact	17 Mar 2026	0001827584

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+26,287	+37%		97,104	15 Mar 2026	Direct	F1
holding	TARS	Common Stock						475	15 Mar 2026	By daughter	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Restricted Stock Units	Options Exercise		-5,097	-100%	$0.000000^*	0	15 Mar 2026	Common Stock	5,097		Direct	F3, F4
transaction	TARS	Restricted Stock Units	Options Exercise		-8,148	-50%	$0.000000^*	8,148	15 Mar 2026	Common Stock	8,148		Direct	F3, F5
transaction	TARS	Restricted Stock Units	Options Exercise		-8,020	-33%	$0.000000^*	16,040	15 Mar 2026	Common Stock	8,020		Direct	F3, F6
transaction	TARS	Restricted Stock Units	Options Exercise		-5,022	-25%	$0.000000^*	15,067	15 Mar 2026	Common Stock	5,022		Direct	F3, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2	This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
F3	Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
F4	RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
F5	RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
F6	RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
F7	RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.